Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397136 | 0.78 | MAPT (0.49) | POLBPKMKDM4EALDH1A1KMT2A | |
| SCHEMBL3836429 | 0.77 | POLB (0.55) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL6492073 | 0.76 | POLB (0.53) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL1371512 | 0.76 | POLB (0.53) | L3MBTL1POLBTDP1PKMKDM4E | |
| Hydrochloric Acid SCHEMBL7810688 | 0.76 | POLB (0.53) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL535647 | 0.74 | L3MBTL1 (0.52) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL28290159 | 0.74 | L3MBTL1 (0.56) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL17834703 | 0.74 | POLB (0.52) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL3636522 | 0.74 | L3MBTL1 (0.52) | L3MBTL1POLBTDP1PKMKDM4E | |
| SCHEMBL2690137 | 0.74 | POLB (0.52) | L3MBTL1POLBTDP1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-3468971-B1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3468971-A1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2019-04-17 | — | — | EP | disclosed |
| CN-109563094-A | Acyclic derivatives, their preparation method and the pharmaceutical composition containing them that new (miscellaneous) aryl replaces | 法国施维雅药厂 | 2019-04-02 | — | — | CN | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2268281-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | L3MBTL1 4856/4885POLB 3966/4885TDP1 3532/4885 |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, BCL2, CCNK | L3MBTL1 2532/4885POLB 291/4885TDP1 3866/4885 |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CCNK | L3MBTL1 2532/4885POLB 291/4885TDP1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.